Program
TJ102
A development code.
Its studies are mostly in Ovarian Neoplasms, led by Phrontline Biopharma.
Furthest: phase 2, since Aug 9, 20261 company-led study, 1 open or runningNext primary completion: Sep 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Phrontline Biopharma | 11 open or running | phase 2since Aug 9, 2026 | Aug 9, 2026 | Sep 2029phase 2 · NCT07778498 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 9, 2026First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT07778498 · 150 planned · United States, China
Ahead
- Sep 2029Primary completion: phase 2 study in Ovarian NeoplasmsNCT07778498
TargetBeta
CDH6 →read by rule
“TJ102 is a CDH6/FRa directed antibody conjugate with dual payloads”study text, by rule · the study
Other programs on CDH6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| raludotatug deruxtecan | Merck | phase 3 | 11 |
| Anti-CDH6 Antibody-drug Conjugate SIM0505rule | nextcure-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07778498Ovarian Neoplasms · United States, China | 2 | Recruiting | Sep 2029 | 150 |
How it is read
Names in the registry
- “TJ102”, 1 entry
Codes read as this program: TJ102.
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.